VYGR * Stock Overview A biotechnology company, focuses on the treatment of gene therapy and neurology diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Voyager Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Voyager Therapeutics Historical stock prices Current Share Price US$165.00 52 Week High US$167.00 52 Week Low US$130.00 Beta 0.91 1 Month Change 0% 3 Month Change 0% 1 Year Change n/a 3 Year Change 106.25% 5 Year Change -42.46% Change since IPO -67.95%
Recent News & Updates
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023) Aug 07
Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index Jul 03
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 Jun 15 See more updates
Voyager Therapeutics, Inc. Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease and Anticipates Filing an Investigational New Drug Application with the U.S. Food and Drug Administration and Clinical Trial Application with Health Canada for VY1706 in 2026 Nov 21
Voyager Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 05
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.51 loss in 2Q 2023) Aug 07
Voyager Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 30
Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 2500 Growth Index Jul 03
Voyager Therapeutics, Inc. Appoints Nathan Jorgensen as Chief Financial Officer, Effective July 8, 2024 Jun 15
Voyager Therapeutics, Inc Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease May 18
First quarter 2024 earnings released: US$0.20 loss per share (vs US$3.05 profit in 1Q 2023) May 14
New minor risk - Profitability May 14
Voyager Therapeutics, Inc. Presents Data for Second-Generation, TRACER™?-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials At the Asgct 27th Annual Meeting May 09
Voyager Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Voyager Therapeutics, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
COO & Acting Chief Business Officer recently sold Mex$222k worth of stock Apr 05
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 15
Voyager Therapeutics, Inc. Announces Appointment of Toby Ferguson as Chief Medical Officer, Effective March 25, 2024 Mar 13
Investor sentiment improves as stock rises 19% Mar 06
Full year 2023 earnings released: EPS: US$3.08 (vs US$1.21 loss in FY 2022) Mar 05
Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment Feb 28
Voyager Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 22
Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer's Disease and Advances Program into Late Research Feb 20
Chief Operating Officer recently sold Mex$314k worth of stock Jan 21
New major risk - Shareholder dilution Jan 09 Voyager Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program Dec 06
Voyager Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 31
Voyager Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 29
Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer Jul 11
Voyager Therapeutics, Inc. Appoints George Scangos as Director and as Member of Science and Technology Committee May 10
First quarter 2023 earnings released: EPS: US$3.05 (vs US$0.56 loss in 1Q 2022) May 10
Voyager Therapeutics, Inc. Appoints Grace E. Colón, Ph.D., to Its Board of Directors, Effective on January 1, 2023 Dec 15
Third quarter 2022 earnings released: EPS: US$0.46 (vs US$0.67 loss in 3Q 2021) Nov 10
Voyager Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Voyager Therapeutics, Inc Presents Data Characterizing a Novel CNS Receptor and Demonstrating the Low-Dose Potential of TRACER™ Generated Capsid Families Oct 12 Voyager Therapeutics Appoints Peter Pfreundschuh as CFO, Effective September 19, 2022 Voyager Therapeutics Presents New Data Demonstrating Novel Candidate Therapeutic Antibodies Reduced Tau Pathology in Multiple Preclinical Models Aug 04
Voyager Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Aug 03
Voyager Therapeutics Appoints Catherine J. Mackey, Ph.D. to Its Board of Directors Jul 29
Voyager Therapeutics, Inc. Announces Executive Changes Jun 09
Voyager Therapeutics, Inc. to Present New Preclinical Data on Family of AAV9-Derived Tracer Capsids Demonstrating Cross-Species Central Nervous System (CNS) Transduction May 20
Voyager Therapeutics, Inc. to Present Preclinical Data from Its Vectorized Anti-Her2 Antibody Program and A Novel Aav5-Derived Tracer™ Capsid At the 25Th American Society of Gene and Cell Therapy Annual Meeting May 18
Voyager Therapeutics, Inc., Annual General Meeting, Jun 06, 2022 Apr 22
Mark Levin and Steven Paul Requests Voyager Therapeutics Not to Nominate for Re-Election to the Board Apr 21
Voyager Therapeutics, Inc. Announces Executive Appointments Feb 04
Investor sentiment improved over the past week Oct 13
Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020) Aug 11 Voyager Therapeutics, Inc.(NasdaqGS:VYGR) dropped from Russell 3000E Index
Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates May 12
Voyager Therapeutics Receives FDA Clearance of IND Application for Gene Therapy Candidate VY-HTT01 for Treatment of Huntington’s Disease Apr 27
Investor sentiment deteriorated over the past week Mar 18
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Feb 26
Voyager Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021 Feb 19
Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Voyager Therapeutics, Inc Feb 17
Investor sentiment deteriorated over the past week Feb 04
Neurocrine Biosciences, Inc. Enters into Partial Termination of the Collaboration and License Agreement with Voyager Therapeutics, Inc Feb 03
Pomerantz Law Firm Announces the Filing of Class Action Against Voyager Therapeutics, Inc Jan 24
Wendy Dixon Decides to Resign from the Board and All Committees of Voyager Therapeutics, Inc Jan 16
Revenue beats expectations Nov 14
Third quarter 2020 earnings released: EPS US$2.30 Nov 14 Shareholder Returns VYGR * MX Biotechs MX Market 7D 0% 0% 0% 1Y n/a 0% 0%
See full shareholder returns
Return vs Industry: Insufficient data to determine how VYGR * performed against the MX Biotechs industry .
Return vs Market: Insufficient data to determine how VYGR * performed against the MX Market .
Price Volatility Is VYGR *'s price volatile compared to industry and market? VYGR * volatility VYGR * Average Weekly Movement n/a Biotechs Industry Average Movement 0% Market Average Movement 0% 10% most volatile stocks in MX Market 0% 10% least volatile stocks in MX Market 0%
Stable Share Price: VYGR *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine VYGR *'s volatility change over the past year.
About the Company Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer’s disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer’s disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer’s disease and is in preclinical trial.
Show more Voyager Therapeutics, Inc. Fundamentals Summary How do Voyager Therapeutics's earnings and revenue compare to its market cap? VYGR * fundamental statistics Market cap Mex$7.35b Earnings (TTM ) Mex$180.22m Revenue (TTM ) Mex$2.87b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) VYGR * income statement (TTM ) Revenue US$143.77m Cost of Revenue US$113.16m Gross Profit US$30.61m Other Expenses US$21.58m Earnings US$9.02m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/10/28 00:30 End of Day Share Price 2024/07/31 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Voyager Therapeutics, Inc. is covered by 25 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Jack Allen Baird Aydin Huseynov Benchmark Company
Show 22 more analysts 